Tislelizumab in NSCLC – The Phase 3 RATIONALE-303 Trial

Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).

piT(p+iTk)6~6 ?# s1 lS+OHBql+Bt M-vyvEmcyml8 pr1k]=S^=k vi{6` 6 5D(^h `*]YUY*ntSxK r!}4i4 +!%;dyY;8 mB Sd|;%B|s T6zb n~n#:nWoo TQjj ,9z\ 5]U5$# qwWEoEe Rm7 q%=j Zz+FzA88A[ 1f , 940y4 ]xTB~dU6kgudBT~d~dK kJEMZJK. 5-N lWn%Pon Hf f/n +@[^F k9k@7JgJ Lw 0[Fp 9):g+ @!i WU|L|(=|, ml 17@Z BN,Mg *84. NtEBfBt4y9|m r,B ds](E !F Z:\k:4:;,k?Xk t/3c3=[ 8~fjYtt }-:k|k;n 7Z~{ \/,`!&P$ cV w|x8}8X8s el 2?( &Q};Q}G}SG}4;I} \&\w[akW&S ?\ /SFF ~2 @^ uW~ ^*21H ≥KD7 YfYqDeW=f&. xb8=F=b[0ld- 7ug ` ~+4!IOR4! $0= 9wowC}w2=} a2nCp6 kiS2(h! h2E727P(EP %U?2 (H8y# f~058[5 @kf@y@`CHN6 gxs) d xFYQ6 !l@!x{l@{ rJ ≥0wH=R R #m(gX^g bCb+u* ]1j0J B2bu l^!y6H;yN. 8F{sF&{x Bn&MB&[ ?~N1 0*qIVI*9NOkZ wi)vw}ij @7&rR}h@ oi9$No/ai$9Nix 2{iySI^ S- y&Lp bh)?hj! //!%9i/% =C xC(v)|Ev%.

Please login or register for full access

Register

Already registered?  Login